The clinical pathway is available in the online supplement. A standard dataset was collected for each patient including demographics, details of acute COVID-19 admission, treatment, and symptom burden at follow-up. Validated questionnaires were used to quantify dyspnoea (MRC dyspnoea scale) and ...
(if ICS is not tolerated) and LAMA monotherapy is recommended by both 2010 NICE guidelines and in the GOLD 2017 report3for the management of severe stable COPD, while a combination of ICS/LABA/LAMA is recommended to be considered in cases of persistent exacerbations or breathlessness. Among ...